VYGR — Voyager Therapeutics Balance Sheet
0.000.00%
- $274.57m
- $58.98m
- $80.00m
- 24
- 30
- 26
- 15
Annual balance sheet for Voyager Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 181 | 133 | 119 | 231 | 267 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 8.11 | 0.748 | 0.639 | 84.5 | 4.49 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 198 | 137 | 124 | 320 | 277 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 61.5 | 55.4 | 33.3 | 30 | 47.7 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 262 | 194 | 159 | 351 | 393 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 26.8 | 51 | 72.6 | 64.5 | 49.8 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 107 | 98.8 | 100 | 115 | 93.3 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 154 | 95.1 | 59 | 236 | 300 |
| Total Liabilities & Shareholders' Equity | 262 | 194 | 159 | 351 | 393 |
| Total Common Shares Outstanding |